Maintenance therapy of chronic psychostic patients with a weekly oral dose of R 16 341. A controlled  double-blind study.
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D010880:Piperidines; D010919:Placebos; D011725:Pyridines; D014149:Tranquilizing Agents